Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment

Détails

ID Serval
serval:BIB_7E19BA428430
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment
Périodique
Intensive Care Med
Auteur⸱e⸱s
Guery B. P., Arendrup M. C., Auzinger G., Azoulay E., Borges Sa M., Johnson E. M., Muller E., Putensen C., Rotstein C., Sganga G., Venditti M., Zaragoza Crespo R., Kullberg B. J.
ISSN
1432-1238 (Electronic)
ISSN-L
0342-4642
Statut éditorial
Publié
Date de publication
02/2009
Volume
35
Numéro
2
Pages
206-14
Langue
anglais
Notes
Guery, Benoit P
Arendrup, Maiken C
Auzinger, Georg
Azoulay, Elie
Borges Sa, Marcio
Johnson, Elizabeth M
Muller, Eckhard
Putensen, Christian
Rotstein, Coleman
Sganga, Gabriele
Venditti, Mario
Zaragoza Crespo, Rafael
Kullberg, Bart Jan
eng
Review
Intensive Care Med. 2009 Feb;35(2):206-14. doi: 10.1007/s00134-008-1339-6. Epub 2008 Oct 30.
Résumé
BACKGROUND: Invasive candidiasis and candidemia are frequently encountered in the nosocomial setting particularly in the intensive care unit (ICU). OBJECTIVE AND METHODS: To review the current management of invasive candidiasis and candidemia in non-neutropenic adult ICU patients based on a review of the literature and an European expert panel discussion. RESULTS AND CONCLUSIONS: Empiric and directed treatment for invasive candidiasis are predicated on the hemodynamic status of the patient. Unstable patients may benefit from broad-spectrum antifungal agents, which can be narrowed once the patient has stabilized and the identity of the infecting species is established. In stable patients, a more classical approach using fluconazole may be satisfactory provided that the patient is not colonized with fluconazole resistant strains or there has been recent past exposure to an azole (<30 days). In contrast, pre-emptive therapy is based on the presence of surrogate markers.
Mots-clé
Amphotericin B/*therapeutic use, Antifungal Agents/*therapeutic use, Bacteremia/*blood/*microbiology, Candida albicans/*isolation & purification, Candidiasis/*drug therapy/*microbiology, Fluconazole/*therapeutic use, Humans, *Intensive Care Units
Pubmed
Création de la notice
29/04/2021 10:59
Dernière modification de la notice
30/04/2021 6:38
Données d'usage